1. J.K. Luce, W.G. Thurman, B.L. Isaacs, and R.W. Talley, Clinical Trials with the antitumor agent 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC 45388), Cancer Chemother. Rep. 54: 119 (1970).
2. R.L. Comis, DTIC (NSC 45388) in malignant melanoma: a perspective, Cancer Treat. Rep. 60: 165 (1976).
3. A.H. Gerulath, and T.L. Loo, Mechanism of action of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide in mammalian cells in culture, Biochem.Pharmacol. 21: 2335 (1972).
4. N.S. Mizuno, R.W. Becker, and B. Zakis, Effects of 5-(3-methyl-1-ltriazeno)imidazole-4-carboxamide (NSC 407347), An alkylating agent derived from 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC 45388), Biochem. Pharmacol. 24: 115 (1975).
5. R.I. Geran, N.H. Greenberg, M.M. Macdonald, A.M. Schumacher, and B.J. Abbott. Protocols for screening chemical agents and natural products against animal tumors and other biological systems, Cancer Chemother.Rep. 3: 1 (1972).